Insulin Biosimilars Market
Insulin Biosimilars Consumption increasing, attributed to an expanding Diabetic Population Pool
Insulin Biosimilars Market by Biosimilar Type, Disease Indication Type & Region - Forecast 2022 - 2032
Insulin Biosimilars Market Snapshot (2022-2032)
[296 Pages Report] Global insulin biosimilars market demand is anticipated to be valued at US$ 1,468.6 Million in 2022, forecast a CAGR of 14.9% to be valued at US$ 5,876.4Million from 2022 to 2032. Growth is attributed to increase in the number of diabetic patients globally. From 2016-2021 a CAGR of 21.5% was registered for the insulin biosimilars market.
|
Data Points |
Key Statistics |
|
Growth Rate (2016-2021) |
21.5% CAGR |
|
Projected Growth Rate (2022-2032) |
14.9% CAGR |
|
Expected Market Value (2022) |
US$ 1,468.6 Million |
|
Anticipated Forecast Value (2032) |
US$ 5,876.4 Million |
A biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product). This means you can expect the same safety and effectiveness from the biosimilar as you would the reference product
Overall, there are currently 11 biosimilar products approved in the United States, none of which are yet considered interchangeable with their originator product. Biological medicines are synthesized within living organisms utilizing biotechnology processes and include a number of manufactured insulins. Once the patents on these medicines expire, other manufacturers are able to replicate them, producing so-called biosimilars.
Let us know your requirement to get
100% FREE customization
Which are Some Prominent Drivers Spearheading Insulin Biosimilars Market Growth?
Increasing Prevalence of Diabetes Drives Growth of the Insulin Biosimilar Market
The global burden of diabetes is increasing with each passing year. The increase rates are majorly attributed to growing cases of obesity which is a direct outcome of sedentary lifestyle patterns. Inadequate physical activity has rendered individuals highly susceptible to such chronic ailments, thus necessitating the establishment of a robust healthcare infrastructure. As diabetic patients require constant insulin levels monitoring, the scope for insulin biosimilars is widening with each passing day.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Furthermore, the ability of the medical industry to correctly administer biosimilars, without triggering any side effects, shall enable the inflow of fresh revenues into the global insulin biosimilars market.
Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market.
What are the Challenges Faced by the Insulin Biosimilars Industry?
High Cost May Restrain the Growth of the Market
Although the insulin biosimilars market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. Insulin patent protection rights and strong retaliation from the branded manufacturers has restricted the growth of insulin biosimilar development.
High costs associated with insulin biosimilars and other diabetes treatment approaches pose a significant detriment to their adoption, particularly across low and middle-income countries. These regions have a relatively inferior healthcare infrastructure as they may lack adequate resources to support robust research and development activities.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhy is North America Emerging as an Opportunistic Insulin Biosimilars Market?
Technological Advancement in Healthcare to Boost the Growth of the Market
Over the years, insulin biosimilar sales have risen at a substantial pace across the region and the trend is likely to continue even during the forecast period, owing to the rapid surge in the number of diabetic people, due to rising healthcare spending, favorable government initiatives, and presence of large number of insulin biosimilar market players in the region. North America accounts for a 69.9% share of the global insulin biosimilar market. Also, the presence of leading insulin biosimilar market players such as Sanofi, Lilly, and Biocon Biologics market is expected to witness the fastest growth in overall market over the forecast period.
North America is expected to hold a large share in the global insulin biosimilars market due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, many new products are being introduced.
For instance, in July, the US Food and Drug Administration (FDA) made regulatory history in the assessment of insulin biosimilars. For the first time, the agency approved a biosimilar insulin designated as interchangeable with its brand-name reference product. Semglee is a biosimilar version of Sanofi’s long-acting insulin Lantus (insulin glargine).
How is Europe Contributing to the Growth of the Insulin Biosimilars Market?
Increasing Prevalence of Diabetes in The Region to Propel the Growth of the Market
The Europe insulin market is expected to account for the second largest share in the global market primarily due to early approval for biosimilar which is expected to fuel the market growth. The Europe insulin biosimilar market accounts for 12.5%share of the total global market.
The higher prevalence of diabetes, high-income population, and also due to significant patent protection for brands of biosimilar insulin in Europe boost the growth of the insulin biosimilar market in the region.
For instance, according to the IDF Diabetes Atlas, an estimated 61 million adults (20-79 years) were living with diabetes in the IDF Europe Region in 2021. Therefore, in order to address rising number of diabetes patients and insulin users in the region, more and more manufacturers are trying to market biosimilar insulin which is anticipated to drive the growth of the biosimilar insulin market in the forthcoming years.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Will the Asia Pacific emerge as an Attractive Insulin Biosimilars Market?
As per FMI, the insulin biosimilar market in Asia Pacific is poised to exhibit strong growth on the back of surging technologically advanced research & treatment platforms for the diagnosis of chronic diseases, expanding healthcare infrastructure in the region.
Also, initiatives taken by the government in developing countries like China India to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin biosimilar.
Start-up Scenario
The new entrants in the insulin biosimilars market are continually indulging in several collaborations and highly investing in research and development activities to provide more convenient solutions to industry verticals. Some of the major start-ups that are leading the development of the market are GeneSys Biologics, Generics and Biosimilars Initiative (GaBI),
- GeneSys Biologics, is a privately held clinical-stage biotechnology company. Provides high-quality, safe, effective and affordable insulin biosimilars across the globe.
Market Competition
Some of the key participants present in the global insulin biosimilars market include Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., Pfizer Inc., Biocon, Mylan N.V. Mylan N.V., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A, Ypsomed AG among others.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., Pfizer Inc. , and Biocon, account for considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.
- In April 2022 - Merck, advanced its bioprocessing portfolio with the acquisition of the MAST® (Modular Automated Sampling Technology) platform from Lonza. The MAST® platform is an automated, aseptic bioreactor sampling system developed in Bend, Oregon, USA.
- In September 2021- Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. announced that Express Scripts, a leading pharmacy benefit management organization in the US, will list Biocon Biologics interchangeable biosimilar Insulin Glargine (Semglee*), which will be commercialized by Viatris, as a preferred glargine brand on its National Preferred Formulary® (NPF), which includes more than 28 million lives.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 14.9% from 2022 to 2032 |
|
Expected Market Value (2022) |
US$ 1,468.6 Million |
|
Anticipated Forecast Value (2032) |
US$ 5,876.4 Million |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million, and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Insulin Biosimilars Industry Survey
Global Insulin Biosimilar Market by Biosimilar Type:
- Rapid Acting Biosimilar
- Long Acting Biosimilar
- Premixed Biosimilar
Global Insulin Biosimilar Market by Disease Indication:
- Insulin Biosimilar for Type I Diabetes
- Insulin Biosimilar for Type II Diabetes
Global Insulin Biosimilar Market by Region:
- North America Insulin Biosimilar Market
- Latin America Insulin Biosimilar Market
- Europe Insulin Biosimilar Market
- Asia Pacific Insulin Biosimilar Market
- Middle East & Africa Insulin Biosimilar Market
Frequently Asked Questions
FMI projects the global insulin biosimilars market to expand at a 14.9% value CAGR by 2032
North America is expected to be the most opportunistic with a 69.9% share of the total enterprise key management market
Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., are some prominent insulin biosimilars, and market manufacturers.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2016-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Biosimilar Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Biosimilar Type, 2016-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Biosimilar Type, 2022-2032
5.3.1. Rapid Acting Biosimilars
5.3.2. Long Acting Biosimilars
5.3.3. Premixed Biosimilars
5.4. Y-o-Y Growth Trend Analysis By Biosimilar Type, 2016-2021
5.5. Absolute $ Opportunity Analysis By Biosimilar Type, 2022-2032
6. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Disease Indication Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Disease Indication Type, 2016-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Indication Type, 2022-2032
6.3.1. Type 1 Diabetes
6.3.2. Type 2 Diabetes
6.4. Y-o-Y Growth Trend Analysis By Disease Indication Type, 2016-2021
6.5. Absolute $ Opportunity Analysis By Disease Indication Type, 2022-2032
7. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2016-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Biosimilar Type
8.2.3. By Disease Indication Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Biosimilar Type
8.3.3. By Disease Indication Type
8.4. Key Takeaways
9. Latin America Market Analysis 2016-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Biosimilar Type
9.2.3. By Disease Indication Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Biosimilar Type
9.3.3. By Disease Indication Type
9.4. Key Takeaways
10. Europe Market Analysis 2016-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Biosimilar Type
10.2.3. By Disease Indication Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Biosimilar Type
10.3.3. By Disease Indication Type
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2016-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Malaysia
11.2.1.5. Singapore
11.2.1.6. Australia
11.2.1.7. Rest of Asia Pacific
11.2.2. By Biosimilar Type
11.2.3. By Disease Indication Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Biosimilar Type
11.3.3. By Disease Indication Type
11.4. Key Takeaways
12. MEA Market Analysis 2016-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Biosimilar Type
12.2.3. By Disease Indication Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Biosimilar Type
12.3.3. By Disease Indication Type
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. U.K.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Biosimilar Type
13.1.2.2. By Disease Indication Type
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Biosimilar Type
13.2.2.2. By Disease Indication Type
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Biosimilar Type
13.3.2.2. By Disease Indication Type
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Biosimilar Type
13.4.2.2. By Disease Indication Type
13.5. Rest of Latin America
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Biosimilar Type
13.5.2.2. By Disease Indication Type
13.6. Germany
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Biosimilar Type
13.6.2.2. By Disease Indication Type
13.7. U.K.
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Biosimilar Type
13.7.2.2. By Disease Indication Type
13.8. France
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Biosimilar Type
13.8.2.2. By Disease Indication Type
13.9. Spain
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Biosimilar Type
13.9.2.2. By Disease Indication Type
13.10. Italy
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Biosimilar Type
13.10.2.2. By Disease Indication Type
13.11. Rest of Europe
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Biosimilar Type
13.11.2.2. By Disease Indication Type
13.12. China
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Biosimilar Type
13.12.2.2. By Disease Indication Type
13.13. Japan
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Biosimilar Type
13.13.2.2. By Disease Indication Type
13.14. South Korea
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Biosimilar Type
13.14.2.2. By Disease Indication Type
13.15. Malaysia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Biosimilar Type
13.15.2.2. By Disease Indication Type
13.16. Singapore
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Biosimilar Type
13.16.2.2. By Disease Indication Type
13.17. Australia
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Biosimilar Type
13.17.2.2. By Disease Indication Type
13.18. Rest of Asia Pacific
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Biosimilar Type
13.18.2.2. By Disease Indication Type
13.19. GCC Countries
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Biosimilar Type
13.19.2.2. By Disease Indication Type
13.20. South Africa
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2021
13.20.2.1. By Biosimilar Type
13.20.2.2. By Disease Indication Type
13.21. Israel
13.21.1. Pricing Analysis
13.21.2. Market Share Analysis, 2021
13.21.2.1. By Biosimilar Type
13.21.2.2. By Disease Indication Type
13.22. Rest of MEA
13.22.1. Pricing Analysis
13.22.2. Market Share Analysis, 2021
13.22.2.1. By Biosimilar Type
13.22.2.2. By Disease Indication Type
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Biosimilar Type
14.3.3. By Disease Indication Type
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Eli Lilly & Co
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Boehringer Ingelheim
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Merck & Co
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Pfizer Inc.
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Biocon
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Mylan N.V.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Wockhardt Limited
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. NOVO Nordisk A/S
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Sanofi S.A
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Ypsomed AG
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2016-2032
Table 2: Global Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032
Table 3: Global Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032
Table 4: North America Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 5: North America Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032
Table 6: North America Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032
Table 7: Latin America Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 8: Latin America Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032
Table 9: Latin America Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032
Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 11: Europe Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032
Table 12: Europe Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032
Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032
Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032
Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 17: MEA Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032
Table 18: MEA Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Biosimilar Type, 2022-2032
Figure 2: Global Market Value (US$ Mn) by Disease Indication Type, 2022-2032
Figure 3: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2016-2032
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 7: Global Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032
Figure 8: Global Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032
Figure 9: Global Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032
Figure 10: Global Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032
Figure 13: Global Market Attractiveness by Biosimilar Type, 2022-2032
Figure 14: Global Market Attractiveness by Disease Indication Type, 2022-2032
Figure 15: Global Market Attractiveness by Region, 2022-2032
Figure 16: North America Market Value (US$ Mn) by Biosimilar Type, 2022-2032
Figure 17: North America Market Value (US$ Mn) by Disease Indication Type, 2022-2032
Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032
Figure 23: North America Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032
Figure 24: North America Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032
Figure 28: North America Market Attractiveness by Biosimilar Type, 2022-2032
Figure 29: North America Market Attractiveness by Disease Indication Type, 2022-2032
Figure 30: North America Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Market Value (US$ Mn) by Biosimilar Type, 2022-2032
Figure 32: Latin America Market Value (US$ Mn) by Disease Indication Type, 2022-2032
Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032
Figure 40: Latin America Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032
Figure 43: Latin America Market Attractiveness by Biosimilar Type, 2022-2032
Figure 44: Latin America Market Attractiveness by Disease Indication Type, 2022-2032
Figure 45: Latin America Market Attractiveness by Country, 2022-2032
Figure 46: Europe Market Value (US$ Mn) by Biosimilar Type, 2022-2032
Figure 47: Europe Market Value (US$ Mn) by Disease Indication Type, 2022-2032
Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032
Figure 53: Europe Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032
Figure 55: Europe Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032
Figure 56: Europe Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032
Figure 58: Europe Market Attractiveness by Biosimilar Type, 2022-2032
Figure 59: Europe Market Attractiveness by Disease Indication Type, 2022-2032
Figure 60: Europe Market Attractiveness by Country, 2022-2032
Figure 61: Asia Pacific Market Value (US$ Mn) by Biosimilar Type, 2022-2032
Figure 62: Asia Pacific Market Value (US$ Mn) by Disease Indication Type, 2022-2032
Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032
Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032
Figure 73: Asia Pacific Market Attractiveness by Biosimilar Type, 2022-2032
Figure 74: Asia Pacific Market Attractiveness by Disease Indication Type, 2022-2032
Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032
Figure 76: MEA Market Value (US$ Mn) by Biosimilar Type, 2022-2032
Figure 77: MEA Market Value (US$ Mn) by Disease Indication Type, 2022-2032
Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: MEA Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032
Figure 83: MEA Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032
Figure 85: MEA Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032
Figure 86: MEA Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032
Figure 88: MEA Market Attractiveness by Biosimilar Type, 2022-2032
Figure 89: MEA Market Attractiveness by Disease Indication Type, 2022-2032
Figure 90: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
